Clinical Trial: Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo

U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07253675) titled 'Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo' on Nov. 19.

Brief Summary: To evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Condition: Monkeypox (Mpox)

Intervention: BIOLOGICAL: MVA-SIBP low dose

Participants received one subcutaneous dose of 0.5ml MVA-SIBP low dose on days 0 and 28, respectively, for a total of two doses.

BIOLOGICAL: MVA-SIBP high dose

Participants re...